Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins

Due to the lower efficacy of currently approved live attenuated rotavirus (RV) vaccines in developing countries, a new approach to the development of safe mucosally administered live bacterial vectors is being considered, using probiotic bacteria as an efficient delivery platform for heterologous RV...

Full description

Saved in:
Bibliographic Details
Published in:Archives of virology 2021-04, Vol.166 (4), p.995-1006
Main Authors: Afchangi, Atefeh, Latifi, Tayebeh, Jalilvand, Somayeh, Marashi, Sayed Mahdi, Shoja, Zabihollah
Format: Article
Language:English
Subjects:
Animals
Antigens
Antigens, Viral - genetics
Antigens, Viral - metabolism
Bacteria
Biomedical and Life Sciences
Biomedicine
Combined vaccines
Developing countries
Genetic Vectors
Humans
Infectious Diseases
Lactic acid
Lactic acid bacteria
Lactobacillales - genetics
Lactobacillales - metabolism
LDCs
Medical Microbiology
Microbiota
Mucosa
Neonates
Probiotics
Probiotics - administration & dosage
Review
Rotavirus
Rotavirus - immunology
Rotavirus Infections - prevention & control
Rotavirus Vaccines - administration & dosage
Rotavirus Vaccines - adverse effects
Rotavirus Vaccines - genetics
Single-Domain Antibodies - genetics
Single-Domain Antibodies - metabolism
Vaccines
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - genetics
Vaccines, Synthetic - metabolism
Virology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to the lower efficacy of currently approved live attenuated rotavirus (RV) vaccines in developing countries, a new approach to the development of safe mucosally administered live bacterial vectors is being considered, using probiotic bacteria as an efficient delivery platform for heterologous RV antigens. Lactic acid bacteria (LAB), which are considered food-grade bacteria and normal microbiota, have been utilized throughout history as probiotics and developed since the 1990s as a delivery system for recombinant heterologous proteins. Over the last decade, LAB have frequently been used as a platform for the delivery of various RV antigens to the mucosa. Given the appropriate safety profile for neonates and providing the benefits of probiotics, recombinant LAB-based vaccines could potentially address the need for a subunit RV vaccine. The present review focuses mainly on different recombinant LAB vaccine constructs for RV and their potential as an alternative recombinant vaccine against RV disease.
ISSN:0304-8608
1432-8798
DOI:10.1007/s00705-021-04964-9